MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in its investigational device exemption (IDE) study of the Endurant Stent Graft System, which is designed to enable the non-surgical repair of aortic aneurysms. Key data from this study, now expected in the second half of 2010, will be used to support the pre-market approval (PMA) submission for U.S. approval of Endurant.
